888 South King Street • Honolulu, HI 96813

October 29, 2008



(808) 522-4000 • straubhealth.org

RECEIVED NOV 0 3 2008 DNMS

U.S. Nuclear Regulatory Commission, Region IV 612 E.Lamar Blvd., Suite 400 Arlington, TX 76011-4125

Subject: Notification NRC License No. 53-19126-01 Docket No. 030-14529

Dear License Reviewer:

We have approved Douglas A. Prager, M.D. as an authorized user for byproduct materials listed in 10 CFR 35.100, 35.200, and 35.300. Dr. Prager is currently authorized for these uses on NRC License #53-00458-04 issued to Tripler Army Medical Center. A copy of this license is enclosed.

Please contact our Radiation Safety Consultant, Ronald Frick, at 808-373-7009 if you require additional information.

Sincerely,

Art Gladstone Chief Operations Officer

Enclosure

s,			
NRC FORM 374 U.S. NUCLEAR REGULA	ATORY COMMISSION PAGE <u>1</u> OF <u>5</u> PAGES Amendment No. 83		
MATERIAL	LS LICENSE		
Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations. Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.			
Licensee	In accordance with letter and e-mail dated		
	June 18, 2007, and August 16, 2007, respectively		
1. Department of the Army	3- License number 53-00458-04 is amended in		
Commander, Tripler Army Medical Center	its entirety to read as follows:		
 ATTN: MCHK-PVR (Radiation Safety Officer) Tripler AMC, Hawaii 96859-5000 	 Expiration date September 30, 2011 Docket No. 030-03537 		
The Avid, nawai 30033-3040	S. Docket No. 030-03537 Reference No.		
atomic numbers 1 through 83, except as specified below B. Molybdenum-99 C. Technetium-99m D. lodine-131 E. Xenon-133 F. Any byproduct material with B. Any, except C. Any, except D. Any, except F. Sealed solver B. Any, except C. Any, except F. Sealed solver B. Any, except C. Any, except F. Sealed solver B. Any, except F. Sealed solver B. Any, except B. Any, except C. Any, except F. Sealed solver B. Any, except B. Any, except B. Any, except B. Any, except B. Any, except B. Any, except C. Any, except F. Sealed solver F. Sealed solver B. Any, except B. Any, except F. Sealed solver F. Sealed solver	or physical form8. Maximum amount that licensee may possess at any one time under this licensept sealed sourcesA. Not to exceed 100 millicuries per radionuclide, except for the following isotope: (See Condition 18)pt sealed sourcesB. 8 curiespt sealed sourcesC. 6 curiespt sealed sourcesD. 1 curiept sealed sourcesE. 3 curies		
atomic numbers 1 through 92			
Model MEI	Scientific, Inc. total possession 2 curies		
	urces (lsotopeH.30 millicuries per source, total possession 120G-137)millicuries1		
I. Depleted Uranium I. Shielding	I. 999 kilograms		

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION		
	License Number 53-00458-04	
MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-03537	
	Amendment No. 83	
 Byproduct, source, and/or special 7. Chemical and/or physic nuclear material 	al form 8. Maximum amount that licensee may possess at any one time under this license	
J. Any byproduct material J. Any brachytherap permitted by 10 CFR 35.400 identified in 10 C	•	
K. Samarium-153 K. Any, except seat	d sources K. 300 millicuries	
9. Authorized use:		
A. through E. and K. Medical research, diagnosis, and	therapy <u>In vitro</u> studies. Studies in laboratory	
animals		
F. Calibration and reference standards		
G. For use in an ADAC Laboratories Model Vantage line source housing for SPECT cameras.		
H. For use in an ADAC Laboratories Model MCD/AC sy	stem for attenuation correction.	
 As shielding for linear accelerators, molybdenum-99/ blocks to be used in selected radiation therapy proce 		
J. Any medical brachytherapy use permitted by 10 CFR		
CONDITIONS	** •	
 Licensed material shall be used only at the licensee's faci Medical Center, Hawaii. 		
11. A. Licensed material shall be used by or under the supervision of individuals designated in writing by the Radiation Safety Committee.		
B. The Radiation Safety Officer for this license is MAJ Frank M. Fota.		
C. The Alternate Radiation Safety Officer for this license is Lou N. Shimabuku.		
D. The Authorized Nuclear Pharmacists for this license are LTC Edna Garcia-Pena and CPT Latisha T. Littleton.		
12. A. Sealed sources and detector cells shall be tested for exceed the intervals specified in the certificate of region Commission under 10 CFR 32.210 or under equivale	stration issued by the U.S. Nuclear Regulatory	

		E RADIOACTIVE MATERIA n refer to TAMC Reg 40-37)	Date	: 15 January 2007
THRU	: Radiation Safety Officer		I User and Organiz	•
Health Physics Section		Prager, Douglas A. (1,2,3)		
	Tripler Army Medical Ce		r Medicine Servic	
			Army Medical Co	inter
то	: Radiation Safety Commi	4		
	Tripler Army Medical Ce			
		Ph: 433-6583		Fax: 433-6255
ist of Authorized/	•			
Authorized Use		Supervised U		
Breitweser, James		Akau, Bryan	•	aldo Turciosrios
Brown, Jerry M. (Ashcraft, James		ne, David B.
Delaplain, Calvin		Clark, Willie J.		
Littleton, Latisha'		Kawaoka, Edwa	ard	
Garcia-Pena, Edn	a	Pandya, Jay		
		Lopez, Jose A.		
(2) Use of unseale (3) Use of unseale X Human Us	d byproduct material for	therapeutic administration IAW 10 Cl		an a bha a feannann an tha an
(3) Use of unseale	d byproduct material for	therapeutic administration IAW 10 Cl	FR 35.300.	
(3) Use of unseale	ed byproduct material for se f each radionuclide.)	therapeutic administration IAW 10 Cl	FR 35.300.	
(3) Use of unseale X Human Use Maximum Activity (o X Unsealed	ed byproduct material for se f each radionuclide.)	therapeutic administration IAW 10 C	FR 35.300.	
3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14	d byproduct material for se f each radionuclide.) i	therapeutic administration IAW 10 Cl X Non-Hu X Sealed S	FR 35.300.	
(3) Use of unseale X Human Us Maximum Activity (o	d byproduct material for se f each radionuclide.) 1 1.0 mCi	therapeutic administration IAW 10 Cl X Non-Hu X Sealed S Americium-241	FR 35.300. man Use Sources 15.0 mCi	
(3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromium-51 Cobolt-57	se f each radionuclide.) i 1.0 mCi 5.0 mCi	therapeutic administration IAW 10 C X Non-Hu X Sealed S Americium-241 Bartum-133	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi	
(3) Use of unseale X Human Us Maximum Activity (o X Unsealed Carbon-14 Chromíum-51	se f each radionuclide.) f 1.0 mCi 5.0 mCi 5.0 mCi	therapeutic administration IAW 10 C X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi ***	
(3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromíum-51 Cobolt-57 Cobolt-58 Fluorine-18	se f each radionuclide.) f 1.0 mCi 5.0 mCi 5.0 mCi 5.0 mCi 5.0 mCi	therapeutic administration IAW 10 C X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cesium-137	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi *** 1.0 mCi	
(3) Use of unseale X Human Us Maximum Activity (o X Unsealed Carbon-14 Chromíum-51 Cobolt-57 Cobolt-58	se f each radionuclide.) f 1.0 mCi 5.0 mCi 5.0 mCi 5.0 mCi 200 mCi	therapeutic administration IAW 10 C X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cobalt-57	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi *** 1.0 mCi 50 mCi	
(3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromíum-51 Cobolt-57 Cobolt-58 Fluorine-18 Gallium-67 ndíum-111	d byproduct material for se f each radionuclide.) i 1.0 mCi 5.0 mCi 5.0 mCi 5.0 mCi 200 mCi 50.0 mCi 50.0 mCi	therapeutic administration IAW 10 C X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cesium-137 Cobalt-57 Cobalt-60	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi 1.0 mCi 50 mCi 1.0 mCi	
(3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromium-51 Cobolt-57 Cobolt-58 Fluorine-18 Gallium-67 indium-111 indium-111	se f each radionuclide.) i 1.0 mCi 5.0 mCi 5.0 mCi 5.0 mCi 200 mCi 50.0 mCi 50.0 mCi 50.0 mCi	therapeutic administration IAW 10 Cl X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cesium-137 Cobalt-57 Cobalt-60 Europium-152 Europium-152	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi *** 1.0 mCi 50 mCi 1.0 mCi 0.5 uCi ****	(Byproduot)
(3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromium-51 Cobolt-57 Cobolt-58 Fluorine-18 Gallium-67 ndium-111 ndium-111 odine-123	se f each radionuclide.) f each radionuclide.) f 1.0 mCi 5.0 mCi 5.0 mCi 5.0 mCi 200 mCi 50.0 mCi 50.0 mCi 50.0 mCi 1.0 Ci **	therapeutic administration IAW 10 Cl X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cesium-137 Cobalt-57 Cobalt-57 Cobalt-60 Europium-152 Gadolinium-153 Sale S	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi *** 1.0 mCi 50 mCi 1.0 mCi 0.5 uCi **** 600 mCi	
(3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromíum-51 Cobolt-57 Cobolt-58 Fluorine-18 Gallium-67 indium-111 ndium-111 odine-123 odine-125	se f each radionuclide.) f each radionuclide.) f 1.0 mCi 5.0 mCi 5.0 mCi 5.0 mCi 200 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 3.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi	therapeutic administration IAW 10 C X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cobalt-57 Cobalt-57 Cobalt-57 Cobalt-60 Europium-152 Gadolinium-153 Germanium-68	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi 50 mCi 1.0 mCi 0.5 uCi **** 600 mCi 50.0 mCi	
(3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromium-51 Cobolt-57 Cobolt-58 Fluorine-18 Gallium-67 ndium-111 ndium-111 odine-123 odine-125 odine-131	d byproduct material for se f each radionuclide.) 1 1.0 mCi 5.0 mCi 5.0 mCi 5.0 mCi 200 mCi 50.0 mCi 50.0 mCi 50.0 mCi 1.0 ci ** 3.0 mCi 250 uCi	therapeutic administration IAW 10 Cl X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-133 Cesium-137 Cobalt-57 Cobalt-57 Cobalt-60 Europium-152 Gadolinium-153 Germanium-68 Germanium-68 Germanium-68	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi 50 mCi 1.0 mCi 0.5 uCi **** 600 mCi 50.0 mCi 3.0 mCi (NAR	
3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromium-51 Cobolt-57 Cobolt-58 Pluorine-18 Gallium-67 ndium-111 ndium-111 odine-123 odine-125 odine-131 Molybdenum-99	d byproduct material for se f each radionuclide.) i 1.0 mCi 5.0 mCi 5.0 mCi 5.0 mCi 200 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 600 mCi	therapeutic administration IAW 10 C X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cesium-137 Cobalt-57 Cobalt-57 Cobalt-60 Europium-152 Gadolinium-153 Germanium-68 Gormanium-68 Radium-226	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi 50 mCi 1.0 mCi 0.5 uCi **** 600 mCi 50.0 mCi 3.0 mCi (NAR 5.0 mg	
(3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromium-51 Cobolt-57 Cobolt-58 Fluorine-18 Gallium-67 indium-111 indium-111 odine-123 odine-125 odine-131 Molybdenum-99 Phosphorus-32	ad byproduct material for 58 of each radionuclide.) 1 1.0 mCi 5.0 mCi 5.0 mCi 200 mCi 50.0 mCi 600 mCi 600 mCi 6.0 Ci	therapeutic administration IAW 10 C X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cesium-137 Cobalt-57 Cobalt-57 Cobalt-60 Europium-152 Gadolinium-153 Germanium-68 Gormanium-68 Radium-226	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi *** 1.0 mCi 50 mCi 1.0 mCi 0.5 uCi **** 600 mCi 50.0 mCi 3.0 mCi 50.0 mCi 2.5 mCi	M)
3) Use of unseale K Human Use Maximum Activity (o X Unsealed Carbon-14 Chromium-51 Cobolt-57 Cobolt-58 Fluorine-18 Callium-67 ndium-111 ndium-111 odine-123 odine-125 odine-131 Molybdenum-99 Phosphorus-32 Samarium-153	d byproduct material for feach radionuclide.) f each radionuclide.	therapeutic administration IAW 10 C X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cobalt-57 Cobalt-57 Cobalt-60 Europium-152 Gadolinium-153 Germanium-68 Germanium-68 Radium-226 Strontium-90	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi *** 1.0 mCi 50 mCi 1.0 mCi 0.5 uCi **** 600 mCi 50.0 mCi 3.0 mCi 50.0 mCi 2.5 mCi 2.5 mCi	M)
(3) Use of unseale X Human Us Maximum Activity (o X Unsealed Carbon-14 Chromíum-51 Cobolt-57 Cobolt-58 Fluorine-18 Gallium-67 Indium-111 Indium-111 Indium-111 Indium-111 Molybdenum-99 Phosphorus-32 Samarium-153 Strontium-89	d byproduct material for feach radionuclide.) f each radionuclide.) f each radionuclide.) f 1.0 mCi 5.0 mCi 5.0 mCi 200 mCi 50.0 mCi 50.0 mCi 50.0 mCi 250 uCi 600 mCi 6.0 Ci 50.0 mCi 200 mCi 200 mCi	therapeutic administration IAW 10 Cl X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cosalt-57 Cobalt-57 Cobalt-57 Cobalt-60 Europium-152 Gadolinium-153 Germanium-68 Gormanium-68 Radium-226 Strontium-90 *For imaging, localization, uptake, di	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi *** 1.0 mCi 50 mCi 1.0 mCi 0.5 uCi **** 600 mCi 3.0 mCi 3.0 mCi 50.0 mCi 1.0 mCi 1.	M) udies.
3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromium-51 Cobolt-57 Cobolt-58 Pluorine-18 Gallium-67 ndium-111 ndium-111 ndium-113 odine-123 odine-125 odine-131 Molybdenum-99 Phosphorus-32 Samarium-153 Strontium-89 Pechnetium-99m	ad byproduct material for se of each radionuclide.) 1 1.0 mCi 5.0 mCi 5.0 mCi 200 mCi 200 mCi 50.0 mCi 50.0 mCi 200 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 50.0 mCi 600 mCi 6.0 Ci 50.0 mCi 200 mCi 50.0 mCi 50.0 mCi	therapeutic administration IAW 10 Cl X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cesium-137 Cobalt-57 Cobalt-57 Cobalt-57 Cobalt-57 Cobalt-60 Europium-152 Gadolinium-153 Germanium-68 Germanium-68 Radium-226 Strontium-90 *For imaging, localization, uptake, dii **For therapeutic use.	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi 50 mCi 1.0 mCi 0.5 uCi **** 600 mCi 50.0 mCi 3.0 mCi 3.0 mCi (NAR 5.0 mg 25 mCi hution and excretion str 0 mCi (NRC License International Structures International International Structures International Structures International S	M) udies.
(3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromíum-51 Cobolt-57 Cobolt-58 Fluorine-18 Gallium-67 Indium-111 Indium-111 Indium-111 Indium-113 odine-123 odine-125 odine-131 Molybdenum-99 Phosphorus-32 Samarium-153 Strontium-89 Fechnetium-99m Challium-201	ad byproduct material for se of each radionuclide.) i 1.0 mCi 5.0 mCi 5.0 mCi 5.0 mCi 200 mCi 50.0 mCi 600 mCi 600 mCi 6.0 Ci 50.0 mCi 200 mCi 50.0 Ci 75 mCi	therapeutic administration IAW 10 Cl X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cosalt-57 Cobalt-57 Cobalt-57 Cobalt-60 Europium-152 Gadolinium-153 Germanium-68 Germanium-68 Radium-226 Strontium-90 *For imaging, localization, uptake, di ***For therapeutic use. ***Maximum activity per source is 30	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi 50 mCi 1.0 mCi 0.5 uCi **** 600 mCi 50.0 mCi 3.0 mCi 3.0 mCi (NAR 5.0 mg 25 mCi hution and excretion str 0 mCi (NRC License International Structures International International Structures International Structures International S	M) udies.
(3) Use of unseale X Human Use Maximum Activity (o X Unsealed Carbon-14 Chromíum-51 Cobolt-57 Cobolt-58 Fluorine-18 Gallium-67 Indium-111 Indium-111 Indium-113 Iodine-123 Iodine-125 Iodine-131 Molybdenum-99 Phosphorus-32 Samarium-153 Strontium-89 Fechnetium-99m	ad byproduct material for se of each radionuclide.) 1 1.0 mCi 5.0 mCi 5.0 mCi 200 mCi 50.0 mCi 200 mCi 50.0 mCi 200 mCi 50.0 mCi 200 mCi 50.0 mCi 50.0 mCi 250 uCi 600 mCi 6.0 Ci 50.0 mCi 200 mCi 50.0 Ci 75 mCi 100 mCi	therapeutic administration IAW 10 Cl X Non-Hu X Sealed S Americium-241 Barium-133 Cesium-137 Cosalt-57 Cobalt-57 Cobalt-57 Cobalt-60 Europium-152 Gadolinium-153 Germanium-68 Germanium-68 Radium-226 Strontium-90 *For imaging, localization, uptake, di ***For therapeutic use. ***Maximum activity per source is 30	FR 35.300. man Use Sources 15.0 mCi 1.0 mCi 60 mCi 50 mCi 1.0 mCi 0.5 uCi **** 600 mCi 50.0 mCi 3.0 mCi 3.0 mCi (NAR 5.0 mg 25 mCi hution and excretion str 0 mCi (NRC License International Structures International International Structures International Structures International S	M) udies.

Radioactive Material Storage Areas

3A-104 (Pharmacy), 3A-102 (Storage), 3A-105 (Dose Room), 3A-156 (ADAC VERTEX), Siemans Body Sean (3A-159), 3A-005 (Storage)

and the second se		
Conditions of Use (Use additional sheets where necessary)		
(1) Bioassays (a) Bioassays shall be performed some time between 6.72 hours of assaying or	administering radionharmacentical doses	
 (a) Bioassays shall be performed some time between 6-72 hours of assaying or administering radiopharmaceutical doses. (b) Quarterly bioassays shall be performed for all rad workers as specified in TAMC REG 40-37. 		
(b) Quarterly bioassays shall be performed for all rad workers as specified in TAMC REG 40-37. (2) Dose Calibrator - Calibrations of the Dose Calibrators will be done in accordance with the model procedure contained in NRC Regulatory Guide 10.2		
(2) Dose Cambrator - Cambratons of the Dose Cambrators will be tone in accordan NRC Regulatory Guide 10.8 Appendix C. nationally recognized standard or the m (3) Sink		
(a) A disposal log shall be maintained by the laboratory to document the amour	nt of radioactive effluent entering the sewer system on a daily basis.	
(b) Less than 1.0 mCi radioactive material shall enter the sewer system through	approved sinks per month.	
(c) Assume empty glassware contains one percent of the initial activity.		
(4) Ordering		
 (a) An HPO Number shall be obtained prior to ordering any isotopes. (b) Ordering of radiopharmaceuticals shall be limited to radioisotopes specified Appendix K. 	I in this authorization, and in accordance with NRC Reg Guide 10.8,	
(5) Receipt - Package receipt will be in accordance with NRC Reg Guide 10.8, Ap	pendices K and L.	
(6) Written Directive Radiopharmaceuticals		
(a) Any administration of greater than 30 microcuries of either I-125 or I-131.		
(b) Any therapeutic administration of a radiopharmaceutical other than 1-125 or	r I-131.	
(7) Preparation of Written Directive Radiopharmaceiticals - Radiopharmaceutica		
supervision of an authorized Nuclear Medicine Physician, authorized Nuclear Pha (8) Administration of Written Directive Radiopharmaceuticals - Prior to administr	rmacist, Mr. Bryan Akau, or Mr. Edward Kawaoka.	
(a) The written directive will be signed and dated by an appropriately "Authoriz	ed User.".	
(b) All females ages 12 through 60 years of age are required to have a pregnancy	y test within 96 hours before administration. The only exception would	
a documented history of hysterectomy.	and the surface of the structure of the formulation measures benefits	
(c) Oral revisions to the written directive are acceptable if a delay in order to pr (d) Identity of the preting about the write and the indirection is the preting of the		
(d) Identiy of the patient shall be verified as the individual named in the writen directive by more than one method.		
(e) The radiopharmaceutical shall be measured in a dose calibrator in accordance		
(9) Written directives requirements shall be reviewed following every administrati	on of a written directive radiopharmaceutical.	
(10) Shipping - Shipping of radioactive materials is not authorized.		
(11) Temporary Supervised User Authorizations	and a management of the state of the state	
(a) Pharmacy residents/students and radiology residents a "supervised users" for a period not to exceed two consecu	upproved by the TAMC HPS are temporarily authorized to work as	
	pervised users" until they have received the appropriate radiation safety	
training and dosimetry devices from the TAMC HPS.		
(12) Supervision - The degree of supervision of a "supervised user" by an "authori	ized user" shall be commensurate with the experience and training of the	
"supervised user". Revision Sur		
List of Authorized/Supervised Users: Remove Superv		
-		
Add Supervised	i User: Jay Pandya	
Meruiner une A able stars		
Maximum Activity:		
waximum Acuvity:		
Radioactive Material Use Areas:		
Radioactive Material Use Areas: Radioactive Material Storage Areaz:		
Radioactive Material Use Areas:		
Radioactive Material Use Areas: Radioactive Material Storage Areas:		
Radioactive Material Use Areas: Radioactive Material Storage Areaz: Conditions of Use:		
Radioactive Material Use Areas: Radioactive Material Storage Areaz: Conditions of Use: Acknowledgement of responsibilities:	pproved:	
Radioactive Material Use Areas: Radioactive Material Storage Areaz: Conditions of Use: Acknowledgement of responsibilities:	pproved: Jennhon for	
Radioactive Material Use Areas: Radioactive Material Storage Areaz: Conditions of Use: Acknowledgement of responsibilities:	Jennishon for	
Radioactive Material Use Areas: Radioactive Material Storage Areaz: Conditions of Use: Acknowledgement of responsibilities: Douglas A. PRAGER, COL, MC	Jennohon for JAMES A. BREITWESER, COL, MC	
Radioactive Material Use Areas: Radioactive Material Storage Areaz: Conditions of Use: Acknowledgement of responsibilities: Douglas A. PRAGER, COL, MC Principal User	Jennohom for JAMES A. BREITWESER, COL, MC Administrative Official	
Radioactive Material Use Areas: Radioactive Material Storage Areaz: Conditions of Use: Acknowledgement of responsibilities: Douglas A. PRAGER, COL, MC Principal User Approved:	Jennohon for JAMES A. BREITWESER, COL, MC	
Radioactive Material Use Areas: Radioactive Material Storage Areaz: Conditions of Use: Acknowledgement of responsibilities: Douglas A. PRAGER, COL, MC Principal User	Jennohom for JAMES A. BREITWESER, COL, MC Administrative Official	
Radioactive Material Use Areas: Radioactive Material Storage Areaz: Conditions of Use: Acknowledgement of responsibilities: Douglas A. PRAGER, COL, MC Principal User Approved:	Jernshim for JAMES A. BREITWESER, COL, MC Administrative Official	
Radioactive Material Use Areas: Radioactive Material Storage Areaz: Conditions of Use: Acknowledgement of responsibilities: Douglas M. Myen DOUGLAS A. PRAGER, COL, MC Principal User Approved: Management A	Jennohom for JAMES A. BREITWESER, COL, MC Administrative Official	

TAMC FORM 76 / 3 SEPT 2003 / PVR

```

## ACCEPTANCE REVIEW MEMO (ARM)

Licensee: Straub Clinic & Hospital

**Docket No.:** 030-14529

License No.: 53-18126-01

Date of Requested Action: 10-29-2008

Mail Control No.: 472016

Type of Action: Notification

ARM reviewer(s): Torres

## Reviewer Assigned:

| Response | Response Deficiencies Noted During Acceptance Review                                                                                                                                                                                                                     |  |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
|          | <ol> <li>Open ended possession limits. Submit inventory. Limit possession.</li> <li>Submit copies of latest leak test results.</li> <li>Add IC L.C./Fingerprint LC, add SUNSI markings to license.</li> <li>Confirm with licensee if they have NARM material.</li> </ol> |  |

| Reviewer's Init                  | ials: Date:                                                                                                           |
|----------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| □ <sub>Yes</sub> □ <sub>No</sub> | Request for unrestricted release Group 2 or >. Consult with Bravo Branch.                                             |
| □Yes □No                         | Termination request < 90 days from date of expiration                                                                 |
| □Yes □No                         | Expedite (medical emergency, no RSO, location of use/storage not on license, RAM in possession not on license, other) |
| □Yes □No                         | TAR needed to complete action.                                                                                        |
| Branch Chief                     | s and/or HP's Initials: Date:                                                                                         |

| SUNSI Screening according to RIS 2005-31                                                                                                                                                          |  |  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| □Yes ☑No Sensitive and Non-Publicly Available if <u>any</u> item below is checked                                                                                                                 |  |  |
| General guidance:                                                                                                                                                                                 |  |  |
| RAM = or > than Category 3 (Table 1, RIS 2005-31), use Unity Rule<br>Exact location of RAM [suite #, bldg. #, location different from mailing address]<br>(whether = or > than Category 3 or not) |  |  |
| Design of structure and/or equipment (site specific)                                                                                                                                              |  |  |
| Information on nearby facilities                                                                                                                                                                  |  |  |
| Detailed design drawings and/or performance information                                                                                                                                           |  |  |
| Emergency planning and/or fire protection systems                                                                                                                                                 |  |  |
| Specific guidance for medical, industrial and academic (above Category 3):                                                                                                                        |  |  |
| RAM quantities and inventory                                                                                                                                                                      |  |  |
| Manufacturer's name and model number of sealed sources & devices                                                                                                                                  |  |  |
| Site drawings with exact location of RAM, description of facility                                                                                                                                 |  |  |
| RAM security program information (locks, alarms, etc.)                                                                                                                                            |  |  |
| Emergency Plan specifics (routes to/from RAM, response to security events)                                                                                                                        |  |  |
| Vulnerability/security assessment/accident-safety analysis/risk assess                                                                                                                            |  |  |
| Mailing lists related to security response                                                                                                                                                        |  |  |
| Branch Chief's and/or HP's Initials: Date: Date:                                                                                                                                                  |  |  |

<u>12-04</u>-08 DATE

This is to acknowledge the receipt of your letter/application dated 10 - 29 - 08, and to inform you that the initial processing, which includes an administrative review, has been performed.

X

There were no administrative omissions. Your application will be assigned to a technical reviewer. Please note that the technical review may identify other omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card: 

The action you requested is normally processed within days.

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

412016 Your action has been assigned Mail Control Number When calling to inquire about this action, please refer to this mail control number. You may call me at 817-860-8103.

Sincerely,

Jurnahan

NRC FORM 532 (RIV) (10-2008)

Licensing Assistant

| BETWEEN:                                                                 | : (FOR LFMS USE)<br>: INFORMATION FROM LTS                                                                                   |
|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| License Fee Management Branch, ARM<br>and<br>Regional Licensing Sections | Program Code: 02120<br>Status Code: 0<br>Fee Category: 7C<br>Exp. Date: 20150531<br>Fee Comments:<br>Decom Fin Assur Reqd: N |


LICENSE FEE TRANSMITTAL

- A. REGION
- 1. APPLICATION ATTACHED Applicant/Licensee: STRAUB CLINIC & HOSPITAL Received Date: 20081103 Docket No: 3014529 Control No.: 472016 License No.: 53-18126-01 Action Type: Amendment Matification
- 2. FEE ATTACHED Amount: Check No.:
- 3. COMMENTS

Signed Date

- B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / /)
- 1. Fee Category and Amount:
- 2. Correct Fee Paid. Application may be processed for: Amendment Renewal License
- 3. OTHER

Signed Date



\*

.